Indivumed Partners with Oslo University Hospital to Advance Cancer Research

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Indivumed GmbH (“Indivumed”) today announced a joint research collaboration to expand IndivuType by adding digital pathology images and data using cutting-edge technology from the Institute for Cancer Genetics and Informatics (“ICGI”) at Oslo University Hospital, a world leader in the application of Deep Learning and AI in oncology.

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months. The expansion of IndivuType’s digital pathology asset and analysis capacity will allow Indivumed and ICGI to combine the cancer phenotype, as defined by the tumor morphology, with the deep molecular multi-omics characterization of the tumor, resulting in better prognostic and diagnostic algorithms which will aid in the personalized treatment of cancer. Furthermore, the project will use the multi-omics data to unlock the black box of Deep Learning to create completely novel insights into tumor biology.

“We are constantly driven by our mission to unveil the complex mechanisms of cancer in order to advance precision oncology,” said Roald Forsberg, PhD, Indivumed Chief Business Officer and Head of the IndivuType Business Unit. “Our collaboration with the renowned ICGI team at Oslo University Hospital is truly unique in that it will result in the creation of the world’s first data asset to combine full multi-omics data with clinical and digital pathology data.”

Indivumed will work closely with the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital to leverage artificial intelligence algorithms to deliver a fully automated method of prognosis for colorectal cancer. IndivuType will utilize the analytical data generated from the standardized global collection of thousands of high-quality patient samples to validate the prognosis method and identify multi-omic signatures that can explain the underlying biology behind the algorithm. The resulting discoveries will be used to explore new avenues of cancer treatment and prevention.

“The success of our program relies on a unique combination of academic and industrial competence using artificial intelligence and digital tools in pathology,” said Professor Håvard E. Danielsen, Director of the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. “Working with Indivumed and the tremendous amount of high-quality data contained within the IndivuType discovery solution will help us to better understand the underlying biology of colorectal cancer and more accurately identify potential biomarkers and therapeutic targets.”

Indivumed and the Institute for Cancer Genetics and Informatics at Oslo University Hospital expect to publish several papers detailing the outcomes of the collaboration and explore commercial opportunities based on the refinement of prognostic algorithms and the discovery of novel insights into the molecular drivers of cancer morphology and biology.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles